ATE153031T1 - Peptid für die stimulierung von für hepatitis c virus spesifischen cytotoischen t lymphozyten - Google Patents

Peptid für die stimulierung von für hepatitis c virus spesifischen cytotoischen t lymphozyten

Info

Publication number
ATE153031T1
ATE153031T1 AT93915244T AT93915244T ATE153031T1 AT E153031 T1 ATE153031 T1 AT E153031T1 AT 93915244 T AT93915244 T AT 93915244T AT 93915244 T AT93915244 T AT 93915244T AT E153031 T1 ATE153031 T1 AT E153031T1
Authority
AT
Austria
Prior art keywords
virus
peptide
ctl
hepatitis
recognize
Prior art date
Application number
AT93915244T
Other languages
English (en)
Inventor
Jay A Berzofsky
Mutsunori I Shirai
Idai Ikenobe
Toshitaka Akatsuka
Stephen M Feinstone
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE153031T1 publication Critical patent/ATE153031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93915244T 1992-06-10 1993-06-10 Peptid für die stimulierung von für hepatitis c virus spesifischen cytotoischen t lymphozyten ATE153031T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/894,063 US5980899A (en) 1992-06-10 1992-06-10 Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells

Publications (1)

Publication Number Publication Date
ATE153031T1 true ATE153031T1 (de) 1997-05-15

Family

ID=25402543

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915244T ATE153031T1 (de) 1992-06-10 1993-06-10 Peptid für die stimulierung von für hepatitis c virus spesifischen cytotoischen t lymphozyten

Country Status (11)

Country Link
US (1) US5980899A (de)
EP (1) EP0644894B1 (de)
JP (1) JP3510249B2 (de)
AT (1) ATE153031T1 (de)
AU (1) AU669193B2 (de)
CA (1) CA2135278C (de)
DE (1) DE69310734T2 (de)
DK (1) DK0644894T3 (de)
ES (1) ES2104156T3 (de)
GR (1) GR3024462T3 (de)
WO (1) WO1993025575A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
CA2195642A1 (en) * 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
AU773000C (en) * 1994-07-27 2004-10-07 Csl Limited Polyepitope vaccines
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
GB9618119D0 (en) 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
US6228576B1 (en) 1997-12-11 2001-05-08 Smithkline Beecham Corporation Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds
EP1200109A4 (de) * 1999-07-19 2005-06-15 Epimmune Inc Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c
EP1307130A4 (de) 2000-02-04 2005-01-12 Beth Israel Hospital Impfstoff gegen menschlichen immunschwächevirus
WO2001072331A1 (en) * 2000-03-31 2001-10-04 Vaccine Chip Technology Aps Immunostimulating properties of a fragment of tgf-beta
AU2000273396A1 (en) * 2000-09-01 2002-03-22 Epimmune, Inc. Hla binding peptides and their uses
US7326536B2 (en) * 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
FR2828934B1 (fr) * 2001-08-27 2004-08-13 Inst Nat Sante Rech Med Test de l'immunite cellulaire par des peptides fixes sur support solide
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
JP2009510122A (ja) * 2005-09-29 2009-03-12 ザ スクリプス リサーチ インスティテュート ウイルスペプチドおよびフラビウイルス科のウイルスに対してウイルス感染を阻害するためのその使用
EP1989326A4 (de) 2006-01-17 2009-09-30 Health Research Inc Heteroduplex-verfolgungstest
CN112601548A (zh) * 2018-03-16 2021-04-02 艾伯塔大学理事会 丙型肝炎病毒肽组合物及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines

Also Published As

Publication number Publication date
ES2104156T3 (es) 1997-10-01
WO1993025575A1 (en) 1993-12-23
DE69310734T2 (de) 1998-01-15
DK0644894T3 (da) 1997-12-08
AU4530093A (en) 1994-01-04
CA2135278A1 (en) 1993-12-23
AU669193B2 (en) 1996-05-30
EP0644894B1 (de) 1997-05-14
JP3510249B2 (ja) 2004-03-22
CA2135278C (en) 2005-08-09
EP0644894A1 (de) 1995-03-29
GR3024462T3 (en) 1997-11-28
US5980899A (en) 1999-11-09
JPH08501282A (ja) 1996-02-13
DE69310734D1 (de) 1997-06-19

Similar Documents

Publication Publication Date Title
ATE153031T1 (de) Peptid für die stimulierung von für hepatitis c virus spesifischen cytotoischen t lymphozyten
Rottier et al. Predicted membrane topology of the coronavirus protein E1
KR960704923A (ko) HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
Kanai et al. Poly (U) binding activity of hepatitis C virus NS3 protein, a putative RNA helicase
Mizushima et al. Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2
Kurokohchi et al. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region
JP2007516696A5 (de)
IL133056A (en) Polypeptide containing an immunogenic portion of an m. tuberculosis antigen, a variant thereof and pharmaceutical compositions containing same
DE3584260D1 (de) Die synthese eines proteins mittels eines identifizierungspeptids.
CA2143491A1 (en) A novel peptide related to human programmed cell death and dna encoding it
RU2004126135A (ru) Новый цитокин zalpha11-лиганд
KR940703860A (ko) 신규한 사람 쿠니즈형 프로테아제 저해제 및 그의 변이체(a novel human kunitz-type protease inhibitor and variants thereof)
NZ319786A (en) HCV NS3 protein fragments with helicase activity and improved solubility
CA2389206A1 (en) Activation of hcv-specific t cells
KR900016261A (ko) 독사독 폴리펩티드 및 유전적 발현
KR880000589A (ko) 플라비 비루스 항원
Kane et al. Cytolytic T-lymphocyte response to isolated class IH–2 proteins and influenza peptides
BR0309401A (pt) polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo
KR910006483A (ko) 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
MY135991A (en) A vaccine-induced hepatits b viral strain and uses thereof
GR3027636T3 (en) Anti-feline immunodeficiency virus (fiv) vaccines.
DK35891D0 (da) Praktisk taget rent, antigenisk peptid eller protein med en epitop af haemophilus influenzae, dets fremstilling og anvendelse
KR880000579A (ko) 베리셀라-죠스터 바이러스의 생산방법
NO20006456L (no) En mutant human hepatitt B viral stamme og anvendelser derav
PT89041A (pt) Metodo de preparacao de diagnosticos e vacinas nanbv

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee